Supernus Pharmaceuticals, Inc. (SUPN) Bundle
An Overview of Supernus Pharmaceuticals, Inc. (SUPN)
General Summary of Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) was founded in 2005 and is headquartered in Rockville, Maryland. The company specializes in developing and commercializing products for the treatment of central nervous system diseases, particularly epilepsy and attention deficit hyperactivity disorder (ADHD). Supernus has a robust portfolio that includes products such as Qelbree, GOCOVRI, Oxtellar XR, and Trokendi XR.
As of 2024, Supernus reported net product sales of $170.3 million for the three months ended September 30, 2024, compared to $149.0 million for the same period in 2023. For the nine months ended September 30, 2024, net product sales reached $471.3 million, up from $417.9 million in 2023.
Company's Financial Performance in the Latest Financial Reports
In the latest financial report for the third quarter of 2024, Supernus Pharmaceuticals achieved a total revenue of $175.7 million, a 14% increase from $153.9 million in the same quarter of the previous year. The company’s primary growth drivers were increases in sales from Qelbree and GOCOVRI, which saw significant year-over-year growth.
| Metrics | Q3 2024 | Q3 2023 | Change (%) |
|---|---|---|---|
| Net Product Sales | $170.3 million | $149.0 million | 14% |
| Total Revenues | $175.7 million | $153.9 million | 14% |
| Net Earnings | $38.5 million | $(16.0) million | N/A |
| Earnings per Share (Basic) | $0.70 | $(0.29) | N/A |
For the nine months ended September 30, 2024, total revenues were $487.7 million, compared to $443.2 million for the same period in 2023, reflecting a 10% increase. The increase in revenue was attributed to strong sales performance of key products, particularly Qelbree, which grew by 78% year-over-year.
Company's Industry Leadership
Supernus Pharmaceuticals is recognized as a leader in the central nervous system pharmaceutical sector. The company has established a strong market presence with innovative therapies for epilepsy and ADHD. Supernus continues to invest in research and development, with research and development expenses totaling $80.1 million for the nine months ended September 30, 2024, compared to $68.2 million in 2023.
The company’s strategic focus on addressing unmet medical needs and enhancing patient outcomes has positioned it favorably within the industry. With a diverse pipeline and a commitment to innovation, Supernus is well-equipped to navigate the competitive landscape of pharmaceutical development.
Mission Statement of Supernus Pharmaceuticals, Inc. (SUPN)
Company's Mission Statement Overview
Supernus Pharmaceuticals, Inc. (SUPN) aims to improve the lives of patients through the development and commercialization of innovative products for the treatment of central nervous system (CNS) disorders. The mission statement focuses on delivering high-quality pharmaceutical products while maintaining a commitment to research and development.
Core Component 1: Commitment to Patients
Supernus Pharmaceuticals emphasizes its dedication to enhancing patient outcomes. The company aims to address unmet medical needs, particularly in the CNS space. For instance, as of September 30, 2024, Supernus reported net product sales of $170.3 million for the quarter, driven primarily by its flagship products Qelbree and GOCOVRI .
Core Component 2: Focus on Innovation
Innovation is at the heart of Supernus's mission. The company invests significantly in research and development, with expenses reaching $29.0 million for the three months ended September 30, 2024, compared to $22.7 million in the same period of the previous year . This reflects a strategic focus on developing new therapies to meet evolving patient needs.
Core Component 3: Quality and Compliance
Supernus Pharmaceuticals prioritizes the quality of its products and compliance with regulatory standards. The company's financial health supports this commitment, as evidenced by cash and cash equivalents totaling $31.7 million and marketable securities of $371.5 million as of September 30, 2024 . Such financial stability enables continued investment in quality assurance and regulatory compliance, ensuring that products meet the highest standards.
| Financial Metrics | Q3 2024 | Q3 2023 | Change (%) |
|---|---|---|---|
| Net Product Sales | $170.3 million | $149.0 million | 14% |
| R&D Expenses | $29.0 million | $22.7 million | 28% |
| Cash and Cash Equivalents | $31.7 million | $94.9 million | -67% |
| Marketable Securities | $371.5 million | $179.8 million | 107% |
Vision Statement of Supernus Pharmaceuticals, Inc. (SUPN)
Vision Statement Overview
The vision statement of Supernus Pharmaceuticals, Inc. (SUPN) as of 2024 emphasizes the company's commitment to enhancing the quality of life for patients through innovative therapeutics. This vision is centered around a patient-first approach, aiming to address unmet medical needs in the CNS (central nervous system) space.
Innovative Therapeutics
Supernus Pharmaceuticals is dedicated to developing innovative therapeutics that improve patient outcomes. The company focuses on the CNS market, which includes treatments for conditions such as epilepsy, ADHD, and Parkinson's disease. As of September 30, 2024, Supernus reported net product sales of $170.3 million for the third quarter, reflecting a significant increase from $149.0 million in the same quarter of 2023. This growth is attributed to the success of its flagship products, Qelbree and GOCOVRI, among others.
Commitment to Patients
Supernus's vision underscores its commitment to patients and their families. The company aims to provide access to high-quality medicines that meet their needs. In the nine months ended September 30, 2024, the company generated total revenues of $487.7 million, up from $443.2 million in the previous year, which signifies its ability to expand its reach and impact in the market.
Addressing Unmet Medical Needs
A crucial aspect of Supernus's vision is addressing unmet medical needs. The company is actively involved in research and development, with R&D expenses amounting to $29.0 million for the third quarter of 2024, up from $22.7 million in the same quarter of 2023. This investment reflects the company's strategy to innovate and introduce new therapies.
Financial Stability and Growth
Supernus Pharmaceuticals maintains a strong financial position, with cash and cash equivalents totaling $31.7 million and marketable securities of $371.5 million as of September 30, 2024. This financial stability supports the company's vision of sustained growth and innovation in the pharmaceutical sector.
| Financial Metrics | Q3 2024 | Q3 2023 | Change |
|---|---|---|---|
| Net Product Sales | $170.3 million | $149.0 million | +14.0% |
| Total Revenues | $175.7 million | $153.9 million | +14.0% |
| R&D Expenses | $29.0 million | $22.7 million | +27.7% |
| Cash and Cash Equivalents | $31.7 million | $75.1 million | -58.0% |
| Marketable Securities | $371.5 million | $179.8 million | +107.0% |
Strategic Partnerships and Collaborations
To further its vision, Supernus Pharmaceuticals actively seeks strategic partnerships and collaborations. These relationships enhance its ability to innovate and bring new products to market. The company’s equity incentive plan, which was amended in June 2024 to increase the number of shares available for issuance by 4 million, is a testament to its commitment to attracting and retaining top talent to drive its vision forward.
Future Outlook
Looking ahead, Supernus Pharmaceuticals is focused on expanding its pipeline and continuing to deliver value to patients. The company's recent approval of SPN-830, a treatment for Parkinson's disease, aligns with its vision of addressing significant unmet needs in the CNS space. Supernus remains committed to its mission of improving patient lives through innovation and high-quality therapeutic solutions.
Core Values of Supernus Pharmaceuticals, Inc. (SUPN)
Integrity
The core value of integrity at Supernus Pharmaceuticals, Inc. emphasizes ethical conduct in all business dealings. This commitment to integrity ensures that the company maintains trust with stakeholders, including patients, healthcare professionals, and investors.
In 2024, Supernus demonstrated its integrity through transparent reporting practices and adherence to regulatory standards. For instance, the company reported net earnings of $58.5 million for the nine months ended September 30, 2024, showcasing its commitment to accurately reflecting its financial health.
Innovation
Innovation is a cornerstone of Supernus’s mission to develop effective treatments for patients with central nervous system disorders. The company invests significantly in research and development, with R&D expenses totaling $80.1 million for the nine months ended September 30, 2024, up from $68.2 million in the same period of 2023.
Supernus launched several clinical programs, including a Phase 2a study for SPN-817, which aims to treat treatment-resistant seizures. The results from the initial stages indicated a median seizure reduction of 56%.
Collaboration
Collaboration within Supernus fosters a culture of teamwork and shared goals, essential for driving success in the pharmaceutical industry. The company engaged in multiple partnerships in 2024, enhancing its product pipeline and market reach. For example, royalty, licensing, and other revenues increased to $16.4 million for the nine months ended September 30, 2024, compared to $25.3 million for the same period in 2023, reflecting the impact of collaborative efforts.
Excellence
Excellence at Supernus Pharmaceuticals signifies the pursuit of high-quality standards in product development and customer service. The company achieved net product sales of $471.3 million for the nine months ended September 30, 2024, an increase from $417.9 million in 2023, highlighting its commitment to delivering effective therapies.
Furthermore, Supernus's operational efficiency is reflected in a decrease in costs of goods sold to $51.8 million from $64.2 million year-over-year, attributed to improved manufacturing processes.
Accountability
Accountability is critical in ensuring that Supernus Pharmaceuticals meets its commitments to stakeholders. The company’s rigorous reporting and compliance mechanisms are evident in its financial disclosures. As of September 30, 2024, Supernus had total assets of $1.34 billion, up from $1.28 billion at the end of 2023.
Supernus also actively manages its liabilities, with total current liabilities reported at $291.5 million, reflecting their commitment to maintaining a robust financial position.
| Core Value | Description | Key Metrics |
|---|---|---|
| Integrity | Ethical conduct in all dealings | Net earnings: $58.5 million (9M 2024) |
| Innovation | Commitment to R&D and new therapies | R&D expenses: $80.1 million (9M 2024) |
| Collaboration | Partnerships enhancing product pipeline | Royalty revenues: $16.4 million (9M 2024) |
| Excellence | Pursuit of high-quality standards | Net product sales: $471.3 million (9M 2024) |
| Accountability | Ensuring commitments to stakeholders | Total assets: $1.34 billion (Sep 2024) |
Supernus Pharmaceuticals, Inc. (SUPN) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Updated on 16 Nov 2024
Resources:
- Supernus Pharmaceuticals, Inc. (SUPN) Financial Statements – Access the full quarterly financial statements for Q3 2024 to get an in-depth view of Supernus Pharmaceuticals, Inc. (SUPN)' financial performance, including balance sheets, income statements, and cash flow statements.
- SEC Filings – View Supernus Pharmaceuticals, Inc. (SUPN)' latest filings with the U.S. Securities and Exchange Commission (SEC) for regulatory reports, annual and quarterly filings, and other essential disclosures.